|
Exosomal Drug Delivery
|
1R44CA221487-01
|
$719,680
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
1R43CA210817-01A1
|
$152,589
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
1R44CA221539-01
|
$1,206,955
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
1R44CA217336-01A1
|
$759,813
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
1R43CA225169-01
|
$295,205
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
1R44CA224460-01
|
$299,805
|
Daunch, William
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-04
|
$160,384
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-05
|
$135,579
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-07
|
$375,250
|
DIPERSIO, C. MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-29
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of tunneling nanotubes as a novel mode of tumor cell-macrophage communication
|
5F99CA212451-02
|
$44,044
|
HANNA, SAMER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Roles of formins in breast cancer invasion
|
5R21CA205262-02
|
$217,935
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-18
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The Metastatic Cascade: Macrophages Lead the Way
|
5R01CA172451-06
|
$439,400
|
POLLARD, JEFFREY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|